Abstract 4365307: Burden of uncontrolled hypertension in real world practice: Insights from iCaReMe Global Registry
Abstract
Background: Despite extensive evidence of strict blood pressure (BP) control benefits in preventing hypertension (HTN)-related morbidity and mortality, HTN control rates (defined as SBP < 130 mmHg and DBP < 80 mmHg), remain low. Thus, understanding the clinical burden of uncontrolled HTN is crucial. The iCaReMe Global Registry is an opportunity to gain contemporary insights into the socio-demographic, clinical characteristics, management patterns and determinants of uncontrolled HTN in routine care. Research Questions: To describe the real-world clinical burden of uncontrolled HTN and management patterns in patients with cardiovascular-renal-metabolic comorbidities. Methods: The iCaReMe Global Registry (NCT03549754) is a multinational, prospective, observational study assessing the management of HTN, T2DM, CKD, and/or HF. Baseline data of participants with HTN and office BP measures enrolled in 29 countries across six WHO regions between 2018 and 2024 were used for a cross-sectional descriptive analysis of demographic, clinical characteristics and medication. Data were grouped into: Controlled HTN (SBP and DBP<130/80mHg) and uncontrolled HTN (SBP or DBP≥130/80mmHg). Results: We examined 21,837 subjects with HTN and BP measures (mean age: 60.3 years, 52.0% female). Comorbidities included: T2DM in 71.3%, dyslipidemia in 51.3%, CKD in 37.8%, and HF in 15.0%. Overall, 24.6% of patients had SBP and DBP<130/80 mmHg (mean SBP/DBP: 114/67 mmHg), and 75.4% had SBP or DBP ≥130/80 mmHg (mean SBP/DBP: 141/84 mmHg) including 61% with SBP or DBP ≥140/90 mmHg. Patients with uncontrolled HTN, compared to controlled HTN group, were younger (59.8 vs 61.8 years), had higher obesity rates (42.5% vs 34.6%) and had more comorbid CKD (39.3% vs 33.1%). Among those with uncontrolled HTN, 60.2% were prescribed antihypertensive drugs including: 69.0% ACEi/ARB, 38.6% CCB, 17% diuretics, and only 46.2% received two or more antihypertensive drugs. Conclusion: Our findings reveal a significant burden of uncontrolled HTN, affecting 3 out of 4 of the study population, characterized by younger age, obesity, and higher comorbid CKD. Despite established guidelines and readily available medications, adherence to guideline directed medical therapy remains low in this high-risk HTN population. These data highlight the urgent need for improved treatment strategies to better control BP and prevent complications.
Article Details
Authors (12)
Kamlesh Khunti
Mustafa Arici
Carol Pollock
Chien-Ning Huang
Ruben Oswaldo Tinoco-Silva
Clinic Specialized in Diabetes Management in Mexico City IMSS-Bienestar Public Health Services, Mexico, Mexico
Adel El Sayed
Faculty of Medicine - Sohag University, Sohag, Egypt
Esteban Coto
Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca,, Gaithersburg, Maryland, United States
Mikhail Kosiborod
Late-Stage Development (CVRM), BioPharmaceuticals R&D, AstraZeneca,, Boston, Massachusetts, United States
Hisham Farouk
Medical Affairs, AstraZeneca International, Dubai, United Arab Emirates
Karim Salama
Medical Affairs, AstraZeneca International, Dubai, United Arab Emirates
Hardik Vasnawala
Medical Affairs, AstraZeneca International, AstraZeneca India, Ba, India
Ahmed HADAOUI
Medical Affairs, AstraZeneca International, AstraZeneca Algeria, Algiers, Algeria